What this deck covers
This deck focuses on Nonsterile Preparations, giving you a quick way to review the definitions, rules, and examples that matter most for NAPLEX.
Study Nonsterile Preparations in NAPLEX with focused flashcards that help you recognize the idea, recall the key rule, and apply it in practice-style prompts.
0% Complete
What is the USP definition of controlled room temperature for storage labeling purposes?
Tap card or press Space to flip
20–25∘C with permitted excursions per USP. USP defines this range to maintain stability, allowing brief excursions to 15–30°C for real-world conditions.
How well did you know it?
Card 1 / 25
Space to flip · ← / → to move · once flipped, → Got it · ← Still learning
This deck focuses on Nonsterile Preparations, giving you a quick way to review the definitions, rules, and examples that matter most for NAPLEX.
Work through these flashcards in short sessions. Try to answer each prompt before flipping the card, then revisit any cards you miss until the explanation feels automatic.
Answer: 20–25∘C with permitted excursions per USP. USP defines this range to maintain stability, allowing brief excursions to 15–30°C for real-world conditions.
Answer: Reduce particle size and improve dispersion by forming a paste. Levigation minimizes agglomeration and ensures homogeneous mixing in semisolid or liquid preparations.
Answer: Not later than 6 months or earliest ingredient expiration, whichever is earlier. For nonaqueous formulations, USP <795> sets this BUD to limit degradation while considering ingredient stability.
Answer: A compounded preparation not required to be sterile. Nonsterile preparations are compounded drugs intended for routes where sterility is not necessary, such as oral or topical use.
Answer: Levigate with a mineral oil or other oil-miscible agent. Oil-miscible agents like mineral oil ensure compatibility and even dispersion in hydrophobic bases.
Answer: Not later than 14 days when stored at 2–8∘C. Refrigeration slows microbial growth in water-containing orals, justifying the 14-day BUD per USP <795>.
Answer: Dissolve drug directly in vehicle, then QS to final volume. Direct dissolution ensures uniform distribution when the drug dissolves easily without additional steps.
Answer: Nonaqueous preparation: BUD not later than 6 months. Anhydrous ointments lack water, reducing microbial risk, so USP <795> allows up to 6 months at room temperature.
Answer: Compounding components. Compounding components are official USP-NF substances or approved ingredients ensuring quality and safety in preparations.
Answer: Document the actual ingredients, steps, and results for that batch. A CR records specifics of each compounding event to verify compliance, traceability, and quality for that preparation.
Answer: %w/v=mL solutiong solute×100. This formula expresses concentration as grams of solute per 100 mL of solution for liquid preparations.
Answer: USP <795>. USP <795> outlines standards for personnel, facilities, documentation, and quality assurance in nonsterile compounding.
Answer: 6mL. Divide dose by concentration to find volume: 150/25=6 mL for accurate administration.
Answer: Nonsterile compounding (not a CSP). USP categorizes preparations not requiring sterility as nonsterile compounding, distinct from CSPs which must be sterile under <797>.
Answer: Oral liquid (solution or suspension). Oral liquids allow dose adjustment and ease of administration for patients with swallowing difficulties.
Answer: %w/w=g preparationg solute×100. This formula calculates weight-based concentration for solids or semisolids using total preparation weight.
Answer: Standardized recipe and instructions for a compounded preparation. An MFR ensures consistency by detailing ingredients, equipment, procedures, and expected yield for repeated compounding.
Answer: 20mg/mL. 2% w/v means 2 g per 100 mL, equivalent to 20 mg per mL by unit conversion.
Answer: Levigate with a suitable agent, then incorporate vehicle gradually. Levigation creates a smooth paste to suspend insoluble particles evenly before adding the vehicle.
Answer: Geometric dilution. Geometric dilution progressively mixes equal volumes to achieve uniform distribution of potent substances.
Answer: Quantity sufficient to make the final volume or weight. QS indicates adding enough vehicle to reach the desired total volume or weight for accurate concentration.
Answer: 1.2g. 1% w/v is 1 g per 100 mL, so for 120 mL, scale proportionally to determine drug amount.
Answer: Beyond-use date (BUD). BUD indicates the date after which the preparation should not be used, based on stability and microbial risk.
Answer: USP <1163>. USP <1163> focuses on quality assurance programs, including process validation and stability testing for compounded preparations.
Answer: Not later than 30 days. Topical water-containing preparations have higher microbial risk, so USP <795> limits BUD to 30 days at room temperature.